Class I and II epitope regions include K417, E484, and N501, and their mutations could effectively enhance the infection either by enhancing the ACE2 binding (N501Y) (Harvey et al., 2021) or reducing the antibody binding (K417N or E484K) (Harvey et al., 2021). The gene discussed is ACE2; the disease is infection.